West Pharmaceutical Services Inc (WST) stock
WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3032% above fair value
$416.42+5.12 (+1.24%)
Close on Nov 13, 2026Market cap $29.01BP/E 46.7Yield 0.21%
West Pharmaceutical Services ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
West Pharmaceutical Services's ebitda for the twelve months ending Sep 30, 2026 was $964.50M, up 28.1% year over year. For fiscal 2025 it was $756.30M, up 4.3% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $874.60M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $756.30M | +4.3% |
| FY2024 | Dec 31, 2024 | $725.30M | -10.8% |
| FY2023 | Dec 31, 2023 | $813.30M | -4.8% |
| FY2022 | Dec 31, 2022 | $854.60M | -2.3% |
| FY2021 | Dec 31, 2021 | $874.60M | +69.5% |
| FY2020 | Dec 31, 2020 | $516.00M | +29.0% |
| FY2019 | Dec 31, 2019 | $400.00M | +16.0% |
| FY2018 | Dec 31, 2018 | $344.70M | +6.9% |
| FY2017 | Dec 31, 2017 | $322.50M | +12.8% |
| FY2016 | Dec 31, 2016 | $285.90M | +30.8% |
| FY2015 | Dec 31, 2015 | $218.50M | -19.7% |
| FY2014 | Dec 31, 2014 | $272.00M | +9.9% |
| FY2013 | Dec 31, 2013 | $247.60M | +16.8% |
| FY2012 | Dec 31, 2012 | $212.00M | +14.4% |
| FY2011 | Dec 31, 2011 | $185.30M | +13.1% |
| FY2010 | Dec 31, 2010 | $163.90M | -1.0% |
| FY2009 | Dec 31, 2009 | $165.60M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $313.30M | +48.8% |
| Q2 FY2026 | Jun 30, 2026 | $225.30M | +15.5% |
| Q1 FY2026 | Mar 31, 2026 | $222.30M | +51.2% |
| Q4 FY2025 | Dec 31, 2025 | $203.60M | +1.6% |
| Q3 FY2025 | Sep 30, 2025 | $210.60M | +4.5% |
| Q2 FY2025 | Jun 30, 2025 | $195.10M | +18.2% |
| Q1 FY2025 | Mar 31, 2025 | $147.00M | -7.2% |
| Q4 FY2024 | Dec 31, 2024 | $200.30M | – |
| Q3 FY2024 | Sep 30, 2024 | $201.50M | – |
| Q2 FY2024 | Jun 30, 2024 | $165.10M | – |
| Q1 FY2024 | Mar 31, 2024 | $158.40M | – |
See a number that looks wrong?